Results 191 to 200 of about 310,430 (355)
Targeting triple‐negative breast cancer remains challenging due to limited therapies and drug resistance. A sequential theranostic strategy combining palbociclib‐induced senescence (enhancing heat sensitivity via HSP70 downregulation) with an NIR‐II nanoplatform (IQ NPs) for mild photothermal therapy (PTT) and quercetin‐mediated senolysis is developed.
Liya Yu +8 more
wiley +1 more source
Giant Cell Tumor of the Tendon Sheath: Case Series and Review of Literature. [PDF]
Parakh NK, Kumar SK, Jain S, Shah P.
europepmc +1 more source
The limited understanding of IGFR pathway activation hinders its clinical application in HCC. Here, IGFRIL is identified as a novel non‐coding activator of the IGF1R, which recruits PTBP1 to destabilize IGFBP3 mRNA and activates IGF1R, and proposes IGFRIL as a novel actionable target for HCC patients.
Jing Zhang +28 more
wiley +1 more source
Tamoxifen for nodal recurrence of serous borderline ovarian tumour - a case report. [PDF]
Guarneri A +10 more
europepmc +1 more source
An integrative analysis combining in vitro genome‐wide immune screens, in vivo ICB screens, and clinical data mining identifies METTL5 as a key tumor‐intrinsic immune factor. Mechanistic studies further reveal the importance of the METTL5‐ATF4‐SLC7A11/SLC3A2‐ferroptosis axis in modulating antitumor immune responses. These findings highlight METTL5 as a
Jiakai Hou +30 more
wiley +1 more source
Histologic grade and STAS as key predictors of distant recurrence in resected early-stage lung adenocarcinoma: a single-center study. [PDF]
Bonis A +16 more
europepmc +1 more source
Engineering Bacteria as Living Therapeutics in Cancer Therapy
Through synthetic biology approaches, natural bacteria can be genetically programmed into multifunctional living therapeutics. These engineered bacteria are capable of secreting anti‐tumor factors, displaying tumor‐associated antigens on their surface, or undergoing programmed self‐lysis to release therapeutic cargo.
Jiangfeng Chen +6 more
wiley +1 more source

